Unawareness for chronic kidney disease is high in all stages, age groups and comorbidities – and higher in women than in men

Variable definition

Unknown CKD was defined according to the patients’ answer to the question ‘Have you ever been told, that you have kidney disease or kidney stones?’. Laboratory data was centrally analyzed by SynLab, Germany. Serum creatinine was measured using the enzymatic method on a Roche Cobas 6000 C502, eGFR (ml/min/1.73m²) was calculated using the CKD-Epi equation (19).

We categorized age in age groups <50, 50-59, 60-69, 70-79 and ≥80 years.

Intake of anti-hypertensive medication was coded according to the patients’ answer to the respective question. Intake of anti-diabetic medication was coded if participants reported taking medications with an ATC-code starting with A10, indicating anti-diabetic drugs. HbA1c had been measured in 2,471 patients.

An albumin/creatinine ratio (ACR) ≥30 indicated a micro-, an ACR ≥300 a macroalbuminuria. BMI was categorized in <25, 25-<30, 30-<40 and ≥40kg/m². The KDIGO guideline 2012 recommends blood pressure lowering treatment in CKD patients with a blood pressure ≥140mmHg systolic or ≥90mmHg diastolic (18). We used this threshold to define good and less good blood pressure control. We used the threshold of ≥160mmHg systolic or ≥95mmHg diastolic to indicate inadequate blood pressure control. KDIGO defines a HbA1c of <7% as optimal glucose control and recommends a target HbA1c of ∼ 7% in CKD patients (18). We categorized HbA1c in <7, 7-<7.5% 7.5-<9% and >= 9% representing optimal, adequate, less well controlled and, uncontrolled glucose.

Cardiovascular disease was coded as prevalent, if a patient positively answered a question about the history of myocardial infarction, bypass surgery, stroke or heart failure.

For each participant, we estimated the probability of reaching end stage renal disease (ESRD) within the next five years using the Kidney-failure-risk-equation (KFRE). KFRE includes the variables age, sex, serum creatinine and ACR. (20)

We calculated a sum score of comorbidities and unfavorable conditions in relation to CKD to mirror participants’ burden of CKD risk factors. The score included albuminuria, anti-hypertensive medication, anti-diabetic medication, history of cardiovascular disease, anemia, obesity and ≥70 years.

Statistical methods

We estimated the prevalence of CKD unawareness and 95% exact confidence intervals (CI) in all patients, and stratified by age, sex, CKD stage, categories of BMI and blood pressure, anti-hypertensive and anti-diabetic medication, and comorbidities such as anemia, albuminuria, stroke, myocardial infarction or heart failure. In patients taking anti-diabetic medication, we calculated the prevalence of CKD unawareness by category of glucose control. We selected insulin, metformin and metformin-combined drugs for subgroup analysis of diabetic patients, as intake of insulin indicates a more severe diabetes and as metformin is contra-indicated with CKD stage 4. In patients with anti-hypertensive medication, CKD unawareness according to blood pressure categories was calculated. For all selected variables, prevalence ratios (PR) for CKD awareness with 95%-CI were estimated using univariate log-binomial regression models. With categorical variables, the category representing the lowest exposure was used as reference. As we want to describe associations between CKD unawareness and patients’ characteristics to depict the situation in clinical practice, adjustment for confounders is not necessary as stated by Hernan: “if the goal of the observational analysis is purely associational, no adjustment for confounding is necessary” (21). As the size of presented crude PRs and their relevance may be questioned, we nonetheless present sex and age adjusted PRs as well. We did not impute missing values.

All analyses were done in SAS 9.4.

Characteristics of participants

Among 3,334 participants, 2,268 (=68%, 95%-CI: 66%-70%) were unaware of their CKD (Tab. 1). 1,219 (37%) patients were classified as CKD stage 1 or 2. In 1,284 (39%) patients a CKD stage 3a and in 611 (18%) CKD stage 3b was present. 220 (7%) had an even more severely decreased renal function. Mean age of the participants was 73.5 (10.4 standard deviation) years, 2.5% were younger than 50 years. Participants had a high prevalence of CKD related risk factors. Proteinuria was prevalent in 2,018 (62%) patients, 2,967 (89%) reported intake of anti-hypertensive medication. Antidiabetic medication was taken by 1,505 patients (45%) and obesity was registered in 1,414 (43%) patients. Participants who were unaware of their CKD differed from those who knew about their disease in prevalence of macroalbuminuria (8.8% vs 13.6%), anemia (20.1% vs 33.6%) or cardiovascular comorbidities (40.5% vs 48%) (Tab. 1). Median eGFR (ml/min/1.73m²) was higher in the unaware participants (58.4 vs 47.9).

Prevalence of unawareness

Compared to men (66% (64%-68%)), women were more often unaware of their CKD (71% (68%-73%)) (Tab. 2). Combining all CKD stages, unawareness decreased in older age from 78% (68%-87%) in patients <50 years to 66% (62%-69%) in patients aged 80 years and older. Women were in all but one age-group (50-59 years) more often unaware than men (Fig. 1).

• Download figure
• Open in new tab

Fig. 1.

Sex difference in unawareness for chronic kidney disease (CKD) by CKD stage and age groups; prevalence with 95% confidence intervals. German CKD related cohorts (CORE database), 2010.

Unawareness decreased with increasing CKD stage. 82% (80%-84%) of the studies’ participants with CKD stage 1 or 2 were unaware of their CKD. Unawareness amounted to a percentage of 71% (68%-73%) in patients with CKD stage 3a and to 49% (45%-54%) in patients with CKD stage 3b. In patients with CKD stage 4, one out of three patients was unaware of the condition.

Even in patients with CKD-related comorbidities CKD unawareness was high. About two-thirds of patients with a history of cardiovascular diseases, with anti-hypertensive or anti-diabetic medication, with high blood pressure or inadequately controlled HbA1c (>7.5%) did not know about their CKD. Unawareness was lower in patients with macroalbuminuria (58% (53%-64%)), anemia (55% (52%-59%)) and in patients with at least four conditions unfavorable for CKD (58% (53%-62%)) (Fig. 1). Unawareness decreased with increasing risk for ESRD within 5 years. But, still 21% (15%-29%) of the patients with an ESRD risk ≥ 15% did not know about their disease that might lead to renal replacement therapy within the next five years.

Prevalence of unawareness in regard to CKD stages

Stratified according to CKD stage, unawareness decreased with age in CKD stages 1-3a, but increased in later age in later CKD (Tab. 3). While in early CKD, no sex difference in unawareness was visible, women were more often unaware of a CKD in higher CKD stages than men. Eventually, in CKD stage 4, unawareness in women was twice as high than in men (43% (33%-55%) vs. 22% (15%-30%)) (Fig. 1).

Unawareness of CKD remained high in later CKD stages (about 50% in CKD stage 3b and 30% in CKD stage 4) in spite of prevalent additional unfavorable health conditions such as hypertension, diabetes or overweight.

Association between unawareness and comorbidities

Strong obesity (BMI ≥40) (PR= 0.88 (0.77-1.00)), anemia (PR=0.78 (0.73-0.83)), intake of anti-hypertensive medication (PR=0.85 (0.80-0.90)), macroalbuminuria (PR=0.90 (0.82-1.00)) or a history of stroke, heart failure or ischemic heart disease were associated with a lower unawareness in CKD patients (Tab. 2). Microalbuminuria, however, was associated with a higher unawareness for CKD (PR=1.13 (1.07-1.19)).

Unawareness in diabetic and hypertensive patients

In diabetic patients taking insulin, CKD unawareness was lower (PR=65% (62%-69%) than in patients taking metformin or metformin-combined drugs (PR=79% (67%-82%)) (Tab. 4). This difference increased with the increasing CKD stage. Unawareness in CKD stage 4 was higher in diabetic than in non-diabetic patients. Metformin which is contra-indicated in CKD stage 4 was taken by 11 participants; of these 8 (=73%) were unaware of their CKD. Diabetic patients with less well controlled glucose (HbA1c ≥7,5%) showed a lower unawareness of CKD in all CKD stages compared to diabetic patients reaching the recommended HbA1c of <7.5%.

In patients taking anti-hypertensive medication, less well controlled blood pressure was not associated with lower unawareness.

Unawareness in patients, physicians and public

Information on CKD awareness was derived from the participants’ answer to the question whether they had ever been told by their physician that they had a renal disease or kidney stones. Therefore, patients’ unawareness could either derive from a lack of understanding the physicians’ information about their CKD or from their physicians’ unawareness of their CKD. 2009, in a report on the prevalence of patients with chronic diseases in general practice, the authoring physicians did not select CKD as one of 20 relevant diseases and conditions (22), although CKD prevalence in this setting is estimated to be about 30% (23). Guidelines on treatment of hypertension or diabetes are much more familiar in general practice than those dealing with CKD (24). It has been shown that interventions to increase CKD knowledge and awareness in primary care physicians can lead to better CKD diagnoses and risk factor management (25).

In about 80% records of patients in general practice (26) and in hospitalized patients due to cardiovascular events (11), a prevalent CKD was not mentioned in their record, less so in patients with diabetes or obese patients. Even patients treated for CKD are often unaware. In patients from a nephrological outpatient clinic, unawareness of CKD stage 1 or 2 was 40%, and in later stages about 12% (27). In UK, 41% of patients with CKD stage 3 that are documented in their GPs CKD registry were unaware of their disease (28).

The high CKD unawareness in patients at higher age (≥70 years) is disturbing. Age-related physiological changes in pharmacodynamics along with decreasing glomerular filtration require renal monitoring and adjustment of prescription and dosing of drugs. About 90% of the older patients in our study reported intake of anti-hypertensive medication. Therefore, they should regularly visit their GP. In our cohort, with increasing age, in CKD stages 3b and 4 unawareness increased also. Physicians seem reluctant to disclose CKD related laboratory findings to their patients. As it is still discussed when to define CKD as ‘disease’ in the elderly (4), physicians do not want to alarm their patients needlessly, when CKD is still not causing any trouble and worry about over-medicalization. However, an EGFR <30ml/min/1.73m² defining CKD stage 4 should be generally regarded as pathologic. On the other hand, if physicians inform their patients about a renal dysfunction, patients may not grasp the meaning and impact it has on their health (29). In an analyses of primary care encounters, CKD was less often discussed than other conditions and information about CKD was given mostly about technical details as laboratory values (14, 30), although better health information facilitates success in patients’ adherence to treatments (13, 31).

CKD unawareness and additional CKD related risk factors

In our cohort, in 97% of all patients, at least one condition was present which should prompt screening of renal function. But even patients already treated or with diagnostic markers for CKD were often unaware. Albuminuria as marker for CKD seem to trigger renal screening, as unawareness was lower in these patients in our as well as in other cohorts (9). Diabetes, hypertension or cardiovascular diseases were more prevalent in our cohort than in CKD patients in general (32). Diabetic patients are at higher risk for diabetic nephropathy or other renal function disorders. Known diabetes as well as hypertension should trigger monitoring renal function. But, unawareness was about 70% in diabetic or hypertensive patients with CKD stage 3a and 50% in CKD stage 3b. A German study found a similar CKD unawareness in patients with coronary heart disease (11). US studies reported even higher CKD unawareness in patients with diabetes or hypertension (33). In our data, 36% of patients with diabetes and CKD stage 4 were unaware of their CKD. A finding that we find difficult to explain, especially as Metformin, an anti-diabetic drug, is contraindicated then.

Unawareness and high risk of renal failure

In our cohort, 21% of patients with a ≥15% risk for renal failure within five years were not informed about the critical state of their disease. These patients might lack necessary time for preparation for renal replacement options. In patients from NHANES with CKD stages 3-4, unawareness was even higher among those with a KFRE risk of ≥15% (50%) (34).

Gender gap in awareness

The gender gap in CKD awareness was unexpected, especially since this gap increased strongly with decreasing renal function. If unawareness for CKD in higher stages can be associated with higher probability of non-treatment or non-adherence to a treatment, women will have a higher risk for CKD-related adverse health outcomes such as cardiovascular diseases, hospitalizations and premature mortality. In 187 CKD participants with CKD from a German population, sex differences in CKD awareness were not visible (10). A recent analysis of NHANES data found a higher CKD unawareness in women compared to men, but only in the Caucasian participants. Sex differences were smaller than in our cohort (35). The reason, why women are more unaware about a potential critical CKD is difficult to explain. Women were similarly affected by comorbidities which should require renal monitoring by their physician. It could have been expected, that they get information about a CKD in the same manner as men. Women have been shown to be more interested in, and are more active seeking, health-related information than men (36). Men, independent of educational attainment, are less engaged in healthy lifestyles than women (37) including less proactive and preventive behavior (38). Sex differences in treatment and disease outcome are also related to physicians’ bias and unconscious attitudes towards female and male patients (39).

Strengths and limitations

We analyzed a unique large high quality data base on patients with CKD who represent a wide range of relevant comorbidities and ages. Our analyses highlight the extent of CKD unawareness in patients at higher CKD risk in general clinical practice.

However, we do not have information on educational attainment or social status, which might be associated with patient awareness. In German CKD patients, unawareness was not associated with educational attainment (10). As the patients in our cohort took part in a study or register, they might have been more interested in their health than the average patient. Generally, study participants seem to have higher education than the general population (40). Therefore, the prevalence of unawareness in CKD patients in the general population might be underestimated in our analyses.

Conclusion

CKD is even prevalent as other publicly better known chronic diseases as diabetes or coronary heart disease. But, awareness for CKD falls short. Even in a country with universal and free health coverage, guideline-recommended monitoring of renal function in patients at higher risk for CKD do not reach the practice. Most alarmingly, independent of age, women’s unawareness, especially of later CKD stages, is higher than mens’. Potential explanations do require further, more detailed research in general, and gender specific CKD related patient-physician communication and treatment.